📢 Publish Your Research for Free - Full APC Waiver, No Hidden Charges. Submit Your Article Today! Submit Now →

Editor Profile

editor profile image is not found.

Prof. Mehmet Rami Helvaci, M.D.

Professor

Present

Alanya University

Alanya

Turkey

editor profile QR Code is not found.

Prof. Dr. Mehmet Rami Helvacı is a prominent Turkish medical academic and clinician specializing in Internal Medicine. He is currently a Professor (Full) operating a private clinic in Alanya, Turkey.

Birth Year: 1974.

Birthplace: Alanya, Turkey.

Languages: Turkish (Native), English, and German.

Professional & Academic Background:

Current Role: Professor of Internal Medicine at a private clinic.

Academic Affiliations: Previously served as a Professor at the Mustafa Kemal University Medical Faculty in Hatay and has also been affiliated with Dicle University.

Research Output: He has contributed to over 329 publications, focusing extensively on chronic diseases and metabolic conditions.

Editorial Roles: Serves as a peer-review editor for various international medical journals.


Primary Areas of Expertise:

His research and clinical practice focus on the underlying mechanisms and systemic impacts of:

Sickle Cell Diseases (SCD): Including studies on survival, complications like cirrhosis, and the effects of hydroxyurea.

Metabolic Syndrome & Atherosclerosis: Investigating their roles in aging and chronic conditions.

Internal Medicine Disorders: Including irritable bowel syndrome (IBS), chronic gastritis, diabetes, and cardiovascular health.

Inflammatory Conditions: RA (Rheumatoid Arthritis), SLE (Lupus), and COVID-19.

  • Autoimmune Thyroiditis
  • Irritable Bowel Syndrome
  • Atherosclerosis
  • Metabolic Syndrome
  • Aging
  • Sickle Cell Diseases
  • Clinical Hematology
  • Altintas E, Akkus N, Gen R, Helvaci MR, Sezgin O, Oguz D. Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis: An echocardiographic assessment. World Journal of Gastroenterology 2004; 10(15): 2278-2280.
  • Helvaci MR, Seyhanli M. What a high prevalence of white coat hypertension in society! Internal Medicine 2006; 45(10): 671-674.
  • Helvaci MR, Kabay S, Gulcan E. A physiologic events’ cascade, irritable bowel syndrome, may even terminate with urolithiasis. Journal of Health Science 2006; 52(4): 478-481.
  • Helvaci MR, Kaya H, Seyhanli M, Cosar E. White coat hypertension is associated with a greater all-cause mortality. Journal of Health Science 2007; 53(2): 156-160.
  • Helvaci MR, Ozcura F, Kaya H, Yalcin A. Funduscopic examination has limited benefit for management of hypertension. International Heart Journal 2007; 48(2): 187-194.
  • Ozcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome. Ocular Immunology and Inflammation 2007; 15(5): 389-393.
  • Helvaci MR, Kaya H, Yalcin A, Kuvandik G. Prevalence of white coat hypertension in underweight and overweight subjects. International Heart Journal 2007; 48(5): 605-613.
  • Ozer C, Kuvandik G, Gokel Y, Duru M, Helvaci MR. Clinical presentation and laboratory findings of organic phosphorus poisoning. Advances in Therapy 2007; 24(6): 1321-1329.
  • Helvaci MR, Kaya H, Duru M, Yalcin A. What is the relationship between white coat hypertension and dyslipidemia? International Heart Journal 2008; 49(1): 87-93.
  • Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of physical health. Internal Medicine 2008; 47(8): 697-703.
  • Duru M, Nacar A, Yonden Z, Kuvandik G, Helvaci MR, Koc A, Akaydin Y, Oksuz H, Sogut S. Protective effects of N-acetylcysteine on cyclosporine-A-induced nephrotoxicity. Renal Failure 2008; 30(4): 453-459.
  • Helvaci MR, Kaya H, Seyhanli M, Yalcin A. White coat hypertension in definition of metabolic syndrome. International Heart Journal 2008; 49(4): 449-457.
  • Kuvandik G, Duru M, Nacar A, Yonden Z, Helvaci R, Koc A, Kozlu T, Kaya H, Sogüt S. Effects of Erdosteine on Acetaminophen-induced Hepatotoxicity in Rats. Toxicologic Pathology 2008; 36(5): 714-719.
  • Helvaci MR, Sevinc A, Camci C, Yalcin A. Treatment of white coat hypertension with metformin. International Heart Journal 2008; 49(6): 671-679.
  • Helvaci MR, Kaya H, Sevinc A, Camci C. Body weight and white coat hypertension. Pak J Med Sci 2009; 25(6): 916-921.
  • Uçar E, Çetin M, Kuvandik C, Helvaci MR, Güllü M, Hüzmeli C. Hepatitis E virus seropositivity in hemodialysis patients in Hatay province, Turkey. Mikrobiyol Bul 2009; 43(2): 299-302.
  • Gökçe A, Davarcy M, Yalcynkaya FR, Güven EO, Kaya YS, Helvaci MR, Balbay MD. Hereditary behavior of varicocele. J Androl 2010; 31(3): 288-290.
  • Helvaci MR, Kaya H, Gundogdu M. Association of increased triglyceride levels in metabolic syndrome with coronary artery disease. Pak J Med Sci 2010; 26(3): 667-672.
  • Helvaci MR, Kaya H. Effect of sickle cell diseases on height and weight. Pak J Med Sci 2011; 27(2): 361-364.
  • Davarci M, Helvaci MR, Aydin M. What is the relationship between type 2 diabetes mellitus and urolithiasis? Bratisl Lek Listy 2011; 112(12): 714-717.
  • Helvaci MR, Kaya H, Gundogdu M. Gender differences in coronary heart disease in Turkey. Pak J Med Sci 2012; 28(1): 40-44.
  • Helvaci MR, Aydin LY, Aydin Y. Chronic obstructive pulmonary disease may be one of the terminal end points of metabolic syndrome. Pak J Med Sci 2012; 28(3): 376-379.
  • Helvaci MR, Aydin Y, Gundogdu M. Smoking induced atherosclerosis in cancers. HealthMED 2012; 6(11): 3744-3749.
  • Helvaci MR, Aydin LY, Aydin Y. Digital clubbing may be an indicator of systemic atherosclerosis even at microvascular level. HealthMED 2012; 6(12): 3977-3981.
  • Buyukkaya E, Karakas MF, Kurt M, Bilen P, Yalcın F, Celik M, Helvacı R, Kaya H, Ertekin F, Sökmen E, Sen N, Akcay AB. The relation of fragmented QRS with tissue Doppler derived parameters in patients with b-thalassaemia major. Clin Invest Med 2012; 35(5): 334-339.
  • Helvaci MR, Ayyildiz O, Gundogdu M. Gender differences in severity of sickle cell diseases in non-smokers. Pak J Med Sci 2013; 29(4): 1050-1054.
  • Davran R, Helvaci MR, Davarci M. Left renal atrophy. Int J Clin Exp Med 2014; 7(6): 1603-1606.
  • Helvaci MR, Acipayam C, Davran R. Autosplenectomy in severity of sickle cell diseases. Int J Clin Exp Med 2014; 7(5): 1404-1409.
  • Helvaci MR, Aydogan A, Akkucuk S, Oruc C, Ugur M. Sickle cell diseases and ileus. Int J Clin Exp Med 2014; 7(9): 2871-2876.
  • Helvaci MR, Acipayam C, Aydogan A, Akkucuk S, Oruc C, Gokce C. Acute chest syndrome in severity of sickle cell diseases. Int J Clin Exp Med 2014; 7(12): 5790-5795.
  • Helvaci MR, Gokce C, Davran R, Acipayam C, Akkucuk S, Ugur M. Tonsilectomy in sickle cell diseases. Int J Clin Exp Med 2015; 8(3): 4586-4590.
  • Coskun M, Ilhan Ö, Ilhan N, Tuzcu EA, Daglioglu MC, Kahraman H, Elbeyli A, Yarbag A, Helvaci MR. Changes in the cornea related to sickle cell disease: a pilot investigation. Eur J Ophthalmol 2015; 25(6): 463-467.
  • Helvaci MR, Gokce C, Davran R, Akkucuk S, Ugur M, Oruc C. Mortal quintet of sickle cell diseases. Int J Clin Exp Med 2015; 8(7): 11442-11448.
  • Helvaci MR, Gokce C, Sahan M, Hakimoglu S, Coskun M, Gozukara KH. Venous involvement in sickle cell diseases. Int J Clin Exp Med 2016; 9(6): 11950-11957.
  • Helvaci MR, Algin MC, Ozdogu H. Follow up of hepatitis C virus infected patients. Saudi Medical Journal 2006; 27(9): 1429-1431.
  • Kaplanoglu M, Helvaci MR. Scorpion stings in pregnant women: an analysis of 11 cases and review of literature. Clin Exp Obstet Gynecol 2015; 42(2): 228-230.
  • Gulcan E, Helvaci MR, Aksoy KA, Gulcan A, Akcan Y. TGF-ß1 is the possible shared pathogenetic factor on a patient with muscular dystrophy and congenital hepatic fibrosis. Medical Hypotheses 2006; 67(2): 428-429.
  • Helvaci MR, Ozcura F, Hacioglu A, Civi K. A Behcet’s case presenting with central retinal vein occlusion. Türkiye Klinikleri Tıp Bilimleri Dergisi 2008; 28: 403-407.
  • Duru M, Helvaci M, Peker E, Dolapcioglu K, Kaya E. Reptile bite in pregnancy. Hum Exp Toxicol 2008; 27(12): 931-932.
  • Helvaci MR, Sevinc A, Camci C, Keskin A. Atherosclerotic background of cirrhosis in sickle cell patients. Pren Med Argent 2014; 100(2): 127-133.
  • Helvaci MR, Tonyali O, Yaprak M, Abyad A, Pocock L. Increased sexual performance of sickle cell patients with hydroxyurea. World Family Med 2019; 17(4): 28-33.
  • Helvaci MR, Tonyali O, Yaprak M, Abyad A, Pocock L. Rheumatoid arthritis may be one step further of systemic lupus erythematosus. World Family Med 2019; 17(4): 17-20.
  • Helvaci MR, Abyad A, Pocock L. What is the relationship between irritable bowel syndrome, smoking, hypertriglyceridemia and fasting plasma glucose? World Family Med 2019; 17(5): 35-41.
  • Helvaci MR, Tonyali O, Yaprak M, Abyad A, Pocock L. Safety of hydroxyurea in sickle cell diseases. World Family Med 2019; 17(6): 20-25.
  • Helvaci MR, Tonyali O, Abyad A, Pocock L. The safest value of plasma triglycerides. World Family Med 2019; 17(7): 22-27.
  • Helvaci MR, Tonyali O, Abyad A, Pocock L. Smoking may be a cause of hypertriglyceridemia. World Family Med 2019; 17(8): 14-18.
  • Helvaci MR, Abyad A, Pocock L. Smoking-induced endothelial damage may increase plasma triglycerides. World Family Med 2019; 17(9): 37-42.
  • Helvaci MR, Abyad A, Pocock L. The lowest is the safest value of plasma triglycerides. World Family Med 2019; 17(10): 10-15.
  • Helvaci MR, Abyad A, Pocock L. Triglycerides may behave as acute phase reactants in the plasma. World Family Med 2019; 17(11): 28-33.
  • Helvaci MR, Abyad A, Pocock L. The safest upper limit of triglycerides in the plasma. World Family Med 2020; 18(1): 16-22.
  • Helvaci MR, Abyad A, Pocock L. What a low sensitivity of high density lipoproteins in the metabolic syndrome. World Family Med 2020; 18(2): 101-107.
  • Helvaci MR, Abyad A, Pocock L. The safest values of low density lipoproteins in the plasma. World Family Med 2020; 18(4): 18-24.
  • Helvaci MR, Abyad A, Pocock L. The safest values of high density lipoproteins in the plasma. World Family Med 2020; 18(5): 38-44.
  • Helvaci MR, Abyad A, Pocock L. The most desired values of high density lipoproteins in the metabolic syndrome. World Family Med 2020; 18(6): 33-39.
  • Helvaci MR, Abyad A, Pocock L. What a low prevalence of diabetes mellitus between the most desired values of high density lipoproteins in the plasma. World Family Med 2020; 18(7): 25-31.
  • Helvaci MR, Yapyak M, Tasci N, Abyad A, Pocock L. The most desired values of high and low density lipoproteins and triglycerides in the plasma. World Family Med 2020; 18(8): 21-27.
  • Helvaci MR, Davran R, Abyad A, Pocock L. What a high prevalence of rheumatic heart disease in sickle cell patients. World Family Med 2020; 18(9): 80-85.
  • Helvaci MR, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Disappearance of hepatitis C virus antibodies with hydroxyurea therapy in sickle cell diseases. World Family Med 2021; 19(12): 43-49.
  • Helvaci MR, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Familial Mediterranean fever may actually be a persistent inflammatory process on vascular endothelium all over the body. World Family Med 2022; 20(2): 27-32.
  • Helvaci MR, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Pulmonary hypertension and chronic obstructive pulmonary disease in sickle cell diseases. World Family Med 2022; 20(3): 27-35.
  • Helvaci MR, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Positive and negative acute phase reactants in sickle cell diseases. World Family Med 2022; 20(3): 36-42.
  • Helvaci MR, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Acute chest syndrome and pulmonary hypertension in sickle cell diseases. World Family Med 2022; 20(4): 22-31.
  • Helvaci MR, Kayabasi Y, Ceylan A, Dede G, Abyad A, Pocock L. Acute gastrointestinal syndrome. World Family Med 2023; 21(1): 55-63.
  • Helvaci MR, Ozer AR, Ceylan A, Zengin M, Abyad A, Pocock L. What a lower prevalence of diabetes mellitus but higher incidence of dyslipidemia in smokers. World Family Med 2023; 21(2): 26-32.
  • Helvaci MR, Camlibel M, Yuksek B, Sevinc A, Camci C, Abyad A, Pocock L. Acute painful crises may be causes of sudden deaths in sickle cell diseases. World Family Med 2023; 21(5): 37-49.
  • Helvaci MR, Tuncsezen UK, Seckin K, Piral K, Seyhan S, Karabacak AD, Camlibel M, Abyad A, Pocock L. An exaggerated capillary endothelial edema may be the cause of sudden deaths in sickle cell diseases. World Family Med 2023; 21(6): 23-35.
  • Helvaci MR, Tuncsezen UK, Seckin K, Piral K, Seyhan S, Karabacak AD, Camlibel M, Abyad A, Pocock L. Fasting plasma glucose may behave as a positive in mild but as a negative acute phase reactant in moderate and severe inflammatory disorders. World Family Med 2023; 21(6): 36-45.
  • Helvaci MR, Vural A, Onay K, Abyad A, Pocock L. Low-dose warfarin may be a life-saving treatment regimen in sickle cell diseases. World Family Med 2023; 21(7): 21-35.
  • Helvaci MR, Tuncsezen UK, Vural A, Onay K, Davran R, Yaprak M, Abyad A, Pocock L. Autosplenectomy may be a good prognostic sign in sickle cell diseases. World Family Med 2023; 21(8): 19-32.
  • Helvaci MR, Pappel V, Piral K, Caylar A, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of cirrhosis in sickle cell diseases. World Family Med 2023; 21(11): 26-39.
  • Helvaci MR, Cayir S, Halici H, Sevinc A, Camci C, Sencan H, Davran R, Abyad A, Pocock L. Acute chest syndrome and coronavirus disease may actually be genetically determined exaggerated immune response syndromes particularly in pulmonary capillaries. World Family Med 2024; 22(3): 6-16.
  • Helvaci MR, Cayir S, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Terminal endpoints of systemic atherosclerotic processes in sickle cell diseases. World Family Med 2024; 22(5): 13-23.
  • Helvaci MR, Daglioglu MC, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Low-dose aspirin plus low-dose warfarin may be the standard treatment regimen in Buerger's disease. World Family Med 2024; 22(6): 22-35.
  • Helvaci MR, Daglioglu MC, Halici H, Sen C, Sevinc A, Camci C, Abyad A, Pocock L. Anti-inflammatory dose of aspirin plus low-dose warfarin may increase the leg performance in Buerger's disease. World Family Med 2024; 22(7): 31-44.
  • Helvaci MR, Halici H, Erdogan K, Sevinc A, Camci C, Abyad A, Pocock L. Metformin in the treatment of cirrhosis. World Family Med 2024; 22(10): 6-20.
  • Helvaci MR, Kurt GD, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Metformin in the treatment of chronic renal disease. World Family Med 2025; 23(1): 12-27.
  • Helvaci MR, Halici H, Erdogan K, Sevinc A, Camci C, Abyad A, Pocock L. Acarbose in the treatment of chronic obstructive pulmonary disease. World Family Med 2025; 23(2): 37-52.
  • Helvaci MR, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Red blood cell transfusions should be preserved just for emergencies in sickle cell diseases. World Family Med 2025; 23(4): 40-53.
  • Helvaci MR, Helvaci E, Helvaci E, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Early phase of diabetes mellitus may just be a reversible insufficiency of pancreas against excess fat tissue. World Family Med 2025; 23(8): 54-70.
  • Helvaci MR, Helvaci E, Helvaci E, Aydin Y, Aydin LY, Sevinc A, Camci C. Obesity may be an irreversible atherosclerotic endpoint in human body. World Family Med 2026; 24(1): 5-21.
  • Akdemir C, Helvaci R. Evaluation of parasitological laboratory results of a group of people older than 15 years of age in Kutahya. Türkiye Parazitoloji Dergisi 2007; 31(1): 37-40. Turkish.
  • Helvaci MR, Ozer C, Kaya H, Yalcin A. Practical cut off values to determine body mass index. Medical Journal of Malaysia 2008; 63(2): 122-124.
  • Helvaci MR, Kaya H, Algin MC, Yalcin A. A Physiologic Events’ Cascade: Irritable Bowel Syndrome May Even Terminate with Chronic Gastritis. Medical Journal of Malaysia 2008; 63(2): 140-142.
  • Helvaci MR, Algin MC, Kaya H. Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis. The Eurasian Journal of Medicine 2009; 41(3): 158-161.
  • Yokuş O, Yılmaz B, Albayrak M, Balçık ÖŞ, Helvacı MR, Sennaroğlu E. The significance of serum transferrin receptor in diagnosis of the coexistence of anemia of chronic disease and iron deficiency anemia. The Eurasian Journal of Medicine 2011; 43(1): 9-12.
  • Helvaci MR, Kaya H, Gundogdu M. White coat hypertension may be an initial sign of metabolic syndrome. Acta Med Indones 2012; 44(3): 222-227.
  • Helvaci MR, Akcay B, Seyhanli M. Is there any increased risk of coronary artery disease in autoimmune thyroiditis? Ind J Cardiol 2006; 1: 13-16.
  • Helvaci MR, Soyucen E, Seyhanli M, Cimbiz A, Tumkaya M. Mutual Relationship of Hepatitis C Virus Infection with Hepatitis B. Journal of Medical Sciences 2006; 6: 257-261.
  • Helvaci MR, Ozcura F, Ozkan A, Dayıoğlu H. What a high prevalence of autoimmune thyroiditis and thyroidectomy in women. Journal of Medical Sciences 2006; 6: 654-657.
  • Kuvandik G, Helvaci MR, Ozer C, Altintas E, Kaya H, Duru M. Hepatitis C virus infection is probably associated with autoimmune disorders and malignancies but not with autoimmune thyroiditis. Journal of Medical Sciences 2007; 7(7): 1093-1097.
  • Helvaci MR, Seyhanli M, Cimbiz A. Ultrasonography Should Be Accepted as a Diagnostic Criterion for Autoimmune Thyroiditis until Demonstration of New Antithyroidal Antibodies. Research Journal of Medicine and Medical Sciences 2007; 2: 42-44.
  • Helvaci MR, Cosar E, Kabay S. Significant Associations Between Chronic Gastritis, Irritable Bowel Syndrome, and Depression. Research Journal of Medicine and Medical Sciences 2007; 2: 45-47.
  • Helvaci MR, Kaya H, Borazan A, Ozer C. Breaking Points of Life for Major Health Problems. Middle East Journal of Age and Ageing 2007; 4: 6.
  • Helvaci MR, Akdemir C, Kaya H, Ozer C. Dyslipidemia may be an indicator for trend of body weight. World Family Med 2008; 6: 2.
  • Helvaci MR, Kaya H, Ozer C. Aging may be the major determiner factor of excess weight. Middle East Journal of Age and Ageing 2008; 5: 2.
  • Helvaci MR, Kaya H, Ozturk OH. Physical activity and mental stresses may be the major determiner factors of blood lipids. Middle East Journal of Age and Ageing 2011; 8: 5.
  • Helvaci MR, Aydin LY, Maden E, Aydin Y. What is the relationship between hypertriglyceridemia and smoking? Middle East Journal of Age and Ageing 2011; 8(6).
  • Helvaci MR, Aydin LY, Maden E, Aydin Y. Digital clubbing and metabolic syndrome. World Family Med 2011; 9: 10.
  • Helvaci MR, Ozcura F, Inci M. Metabolic syndrome and cataract. Middle East J Intern Med 2012; 5: 29-32.
  • Helvaci MR, Ozcura F, Akin MM. Funduscopic changes in white coat hypertension. World Family Med 2012; 10: 42-46.
  • Helvaci MR, Maden E, Aydin LY, Aydin Y. Chronic obstructive pulmonary disease and metabolic syndrome. Middle East Journal of Age and Ageing 2012; 9: 2.
  • Helvaci MR, Kaya H, Ayyildiz O, Gundogdu M. Obesity should be accepted as one of the irreversible end points of metabolic syndrome. Middle East Journal of Age and Ageing 2012; 9: 3.
  • Helvaci MR, Ozcura F, Kaya H. Corneal arcus has limited beniefit for management of dyslipidemia. Middle East Journal of Age and Ageing 2012; 9: 27-30.
  • Helvaci MR, Kaya H, Dilek I. Smoking, as a pleasure in life, should be accepted as one of the reversible components of metabolic syndrome. Middle East Journal of Age and Ageing 2012; 9(4); 3-7.
  • Helvaci MR, Ari M, Gundogdu M. Body mass index and antisocial personality disorder. Middle East Journal of Psychiatry and Alzheimers 2012; 3: 23-26.
  • Helvaci MR, Ari M, Maden E, Aydin LY, Aydin Y, Ozer C. Effects of season-induced hormonal changes on mortality. World Family Med 2012; 10: 4-7.
  • Helvaci MR, Aydin Y, Gundogdu M. Atherosclerotic effects of smoking and excess weight. J Obes Wt Loss Ther 2012; 2: 7.
  • Cebicci H, Karakus A, Gokce C, Motor S, Zeren C, Yucel M, Gunay N, Helvacı R. The evaluation of the patients admitted with hypoglycemia in an emergency department: from the perspective of an emergency specialist. Middle East J Intern Med 2013; 6: 25-27.
  • Helvaci MR, Tutanc M, Arica V. Metabolic deterioration just after infancy. Middle East J Intern Med 2013; 6(4): 26-30.
  • Helvaci MR, Aydin Y, Gundogdu M. Body mass index or body weight alone. World Family Med 2013; 11(7): 43-47.
  • Helvaci MR, Akkucuk S, Aydogan A. A new treatment approach in tuberculosis. World Family Med 2013; 11(10): 33-36.
  • Helvaci MR, Kaya H, Gundogdu M. Gender differences in patients with metabolic syndrome in coronary artery interventions. Medicinski Glasnik 2013; 10: 75-80.
  • Helvaci MR, Erden ES, Aydin LY. Atherosclerotic background of chronic obstructive pulmonary disease in sickle cell patients. HealthMED 2013; 7(2): 484-488.
  • Helvaci MR, Aydin Y, Ayyildiz O. Clinical severity of sickle cell anemia alone and sickle cell diseases with thalassemias. HealthMED 2013; 7(7): 2028-2033.
  • Helvaci MR, Aydin Y, Ayyildiz O. Hydroxyurea may prolong survival of sickle cell patients by decreasing frequency of painful crises. HealthMED 2013; 7(8): 2327-2332.
  • Helvaci MR, Aydin Y, Aydin LY. Atherosclerotic background of chronic kidney disease in sickle cell patients. HealthMED 2013; 7(9): 2532-2537.
  • Helvaci MR, Ayyildiz O, Gundogdu M. Red blood cell transfusions and survival of sickle cell patients. HealthMED 2013; 7(11): 2907-2912.
  • Helvaci MR, Ayyildiz O, Gundogdu M. Clinical severity of sickle cell diseases in genders. HealthMED 2013; 7: 3132-3137.
  • Helvaci MR, Ayyildiz O, Gundogdu M. Hydroxyurea therapy and parameters of health in sickle cell patients. HealthMED 2014; 8(4): 451-456.
  • Helvaci MR, Aydogan F, Sevinc A, Camci C, Dilek I. Platelet and white blood cell counts in severity of sickle cell diseases. HealthMED 2014; 8(4): 477-482.
  • Helvaci MR, Gokce C. Painful crises and survival of sickle cell patients. HealthMED 2014; 8(5): 598-602.
  • Acipayam C, Kaya S, Helvaci MR, Ilhan G, Oktay G. Very high levels of C-reactive protein should alert the clinicians to the development of acute chest syndrome in sickle cell patients. World Family Med 2014; 12: 4-9.
  • Acipayam C, Dorum BA, Ilhan G, Ersoy A, Oktay G, Helvaci MR. Predictive value of pain intensity in the clinical severity of painful crises in children and adolescents with sickle cell diseases. Middle East J Intern Med 2014; 7: 28-33.
  • Helvaci MR, Sevinc A, Camci C, Keskin A. Smoking and sickle cell diseases. Exp Clin Cardiol 2014; 20: 3706-3722.
  • Helvaci MR, Davran R, Aydogan A, Akkucuk S, Ugur M, Oruc C. Stroke in severity of sickle cell diseases. J Metabolic Synd 2015; 2: 4.
  • Helvaci MR, Gokce C, Davran R, Akkucuk S, Ugur M, Ozcan A. Leg ulcers in severity od sickle cell diseases. Middle East J Intern Med 2015; 8 (3): 7-12.
  • Helvaci MR, Hakimoglu S, Sariosmanoglu MO, Kardas S, Bahar B, Filoglu M, Deler IU, Almali DA, Gokpinar O, Celik O, Ozbay A, Karagoz OI, Aydin S. Preoperative management of sickle cell patients with hydroxyurea. World Family Med 2015; 13 (7): 4-9.
  • Helvaci MR, Dogru S. Chronic obstructive pulmonary disease may be one of the terminal endpoints of the sickle cell diseases. World Family Med 2015; 13 (8): 11-17.
  • Yildizgoren MT, Helvaci MR, Ustun N, Osmanoglu K, Turhanoglu AD. Ultrasonographic assessment of the distal femoral cartilage thickness in patients with homozygous sickle cell disease. Cartilage 2016; 7(3): 217-221.
  • Altinay L, Acipayam M, Fansa I, Lale C, Halici Ü, Davran R, Bayarogullari H, Helvaci MR. Comparative results of the two methods of port catheter application and evaluation of patient comfort with visual analogue scale. Middle East J Intern Med 2015; 8 (4): 3-7.
  • Helvaci MR, Sahan M, Bay F, Yildirim Y, Dede G, Cihangir E, Mermer A, Pocock L. Low-dose aspirin should be initiated for sickle cell patients. Middle East J Intern Med 2016; 9 (1): 3-8.
  • Helvaci MR, Sahan M, Sulhan A, Acik AF, Ocak A, Salaz S, Pocock L. Accelerated atherosclerosis and digital clubbing in sickle cell diseases. World Family Med 2016; 14 (3): 10-16.
  • Helvaci MR, Davran R, Davarci M, Muftuoglu OE, Pocock L. Left renal atrophy in sickle cell diseases. World Family Med 2016; 14 (4): 4-8.
  • Helvaci MR, Atci N, Ayyildiz O, Muftuoglu OE, Pocock L. Red blood cell supports in severe clinical conditions in sickle cell diseases. World Family Med 2016; 14 (5): 11-18.
  • Helvaci MR, Sahan M, Atci N, Ayyildiz O, Muftuoglu OE, Pocock L. Acute chest syndrome does not have a chronic inflammatory background in sickle cell diseases. Middle East J Int Med 2016; 9(2): 12-18.
  • Helvaci MR, Sahan M, Arslanoglu Z, Celikel A, Ayyildiz O, Muftuoglu OE. Atherosclerotic background of disseminated teeth losses in sickle cell diseases. J Med Res 2016; 4: 104-109.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Pocock L. Digital clubbing may be a pioneer sign of cirrhosis in sickle cell patients. Middle East J Intern Med 2016; 9: 12-17.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of benign prostatic hyperplasia in sickle cell diseases. Middle East J Intern Med 2017; 10(1): 3-9.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of hepatomegaly, left lobe hypertrophy, and cirrhosis in sickle cell diseases. Middle East J Intern Med 2017; 10(1): 10-16.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Yaprak M, Abyad A, Pocock L. White coat hypertension may be an initial sign of an accelerated atherosclerotic process. Middle East J Intern Med 2017; 10(2): 27-32.
  • Helvaci MR, Davarci M, Ozkan OV, Semerci E, Abyad A, Pocock L. Cholelithiasis may also be a consequence of metabolic syndrome. World Family Med 2017; 15 (5): 9-13.
  • Helvaci MR, Davarci M, Ozkan OV, Semerci E, Abyad A, Pocock L. Cholelithiasis and cholecystectomy may lower the low density lipoprotein cholesterol in plasma. World Family Med 2017; 15 (7): 8-12.
  • Helvaci MR, Albayrak M, Balcik OS, Celebi H, Abyad A, Pocock L. Moderate iron deficiency anemia in the treatment of metabolic syndrome. Middle East J Intern Med 2017; 10 (3): 23-26.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Gundogdu M, Abyad A, Pocock L. Lower the triglyceride, longer the survival. Middle East J Intern Med 2017; 10 (3): 27-32.
  • Helvaci MR, Davarci M, Ozkan OV, Semerci E, Abyad A, Pocock L. Hypertriglyceridemia may actually be an acute phase reactant in the plasma. EC Cardiology 2017; 3(5): 162-169.
  • Helvaci MR, Ayyildiz O, Algin MC, Aydin Y, Abyad A, Pocock L. Alanine aminotransferase indicates excess weight and dyslipidemia. World Family Med 2017; 15(9): 13-17.
  • Helvaci MR, Ayyildiz O, Algin MC, Aydin Y, Abyad A, Pocock L. Irritable bowel syndrome and smoking. World Family Med 2017; 15(10): 7-11.
  • Helvaci MR, Ayyildiz O, Gundogdu M, Aydin Y, Abyad A, Pocock L. Hyperlipoproteinemias may actually be acute phase reactants in the plasma. World Family Med 2018; 16(1): 7-10.
  • Helvaci MR, Ozkan OV, Akkucuk S, Yaprak M, Abyad A, Pocock L. Inguinal hernia may not have a chronic low-grade inflammatory background on vascular endothelium. World Family Med 2018; 16(2): 32-36.
  • Helvaci MR, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of hepatosteatosis in sickle cell diseases. World Family Med 2018; 16(3): 12-18.
  • Helvaci MR, Algin MC, Abyad A, Pocock L. Physical inactivity or an excessive eating habit. Middle East J Nursing 2018; 12(1): 14-18.
  • Helvaci MR, Davarci M, Inci M, Yaprak M, Abyad A, Pocock L. Chronic endothelial inflammation and priapism in sickle cell diseases. World Family Med 2018; 16(4): 6-11.
  • Helvaci MR, Aydin Y, Varan G, Abyad A, Pocock L. Acarbose versus metformin in the treatment of metabolic syndrome. World Family Med 2018; 16(5): 10-15.
  • Helvaci MR, Abyad A, Pocock L. What a low prevalence of autoimmune thyroiditis in sickle cell diseases. World Family Med 2018; 16(6): 27-32.
  • Helvaci MR, Abyad A, Pocock L. Medical treatment of metabolic syndrome in the fourth decade. Middle East J Intern Med 2018; 11(1): 7-13.
  • Helvaci MR, Ayyildiz O, Ozkan OV, Algin MC, Abyad A, Pocock L. Umbilical hernia may also be a sequel of metabolic syndrome. Middle East J Intern Med 2018; 11(1): 14-19.
  • Helvaci MR, Tekin B, Abyad A, Pocock L. Alarming consequences of the sickle cell diseases. World Family Med 2018; 16(7): 14-21.
  • Helvaci MR, Abyad A, Pocock L. What a low prevalence of rheumatoid arthritis in sickle cell diseases. World Family Med 2018; 16(8): 32-37.
  • Helvaci MR, Ayyildiz O, Sevinc A, Camci C, Abyad A, Pocock L. What a low prevalence of malignancies in sickle cell diseases. World Family Med 2018; 16(9): 4-9.
  • Helvaci MR, Davarci M, Inci M, Aydin Y, Abyad A, Pocock L. Varicocele may not have a chronic low-grade inflammatory background on vascular endothelium. World Family Med 2018; 16(9): 10-14.
  • Helvaci MR, Abyad A, Pocock L. What a low prevalence of systemic lupus erythematosus in sickle cell diseases. Middle East J Intern Med 2018; 11(2): 3-8.
  • Helvaci MR, Arslanoglu Z, Celikel A, Abyad A, Pocock L. Pathophysiology of pulmonary hypertension in sickle cell diseases. Middle East J Intern Med 2018; 11(2): 14-21.
  • Helvaci MR, Ayyildiz O, Algin MC, Aydin Y, Abyad A, Pocock L. Urolithiasis and smoking. World Family Med 2018; 16(10): 9-13.
  • Helvaci MR, Ayyildiz O, Gundogdu M, Aydin Y, Abyad A, Pocock L. Excess weight or smoking. World Family Med 2018; 16(10): 14-19.
  • Helvaci MR, Yaprak M, Aydin Y, Abyad A, Pocock L. Irritable bowel syndrome and metabolic parameters. Middle East J Psychiatry and Alzheimers 2018; 9(2): 15-20.
  • Helvaci MR, Ayyildiz O, Gundogdu M, Aydin Y, Abyad A, Pocock L. Mental health may not have a chronic low-grade inflammatory background on vascular endothelium. Middle East J Age and Aging 2018; 15(1): 3-7.
  • Helvaci MR, Ayyildiz O, Gundogdu M, Aydin Y, Abyad A, Pocock L. Body mass and blood pressure. World Family Med 2019; 17(1): 36-40.
  • Helvaci MR, Algin MC, Abyad A, Pocock L. Smoking may even terminate with irritable bowel syndrome. Middle East Journal of Nursing 2019; 13(1): 25-30.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Gundogdu M, Abyad A, Pocock L. White coat hypertension may actually be an acute phase reactant in the body. World Family Med 2019; 17(3): 12-16.
  • Helvaci MR, Dede G, Yildirim Y, Salaz S, Abyad A, Pocock L. Smoking may even cause irritable bowel syndrome. World Family Med 2019; 17(3): 28-33.
  • Helvaci MR, Tonyali O, Yaprak M, Algin MC, Abyad A, Pocock L. Irritable bowel syndrome, chronic gastritis, smoking, depression, haemorrhoids and urolithiasis. Middle East J Nursing 2019; 13(2): 29-34.
  • Helvaci MR, Abyad A, Pocock L. Smoking-induced endothelial injury triggers plasma triglycerides. Middle East J Nursing 2019; 13(3): 11-17.
  • Helvaci MR, Aydin Y, Abyad A, Pocock L. High density lipoproteins may actually be some negative acute phase proteins in the plasma. Japanese Journal of Gastroenterology and Hepatology 2019; 2(7): 1-7.
  • Helvaci MR, Abyad A, Pocock L. Safer values of low density lipoproteins in the plasma. Japanese Journal of Gastroenterology and Hepatology 2020; 3(2): 1-8.
  • Helvaci MR, Abyad A, Pocock L. Low density lipoproteins act as negative acute phase proteins in the metabolic syndrome. Middle East J Nursing 2020; 14(1): 3-9.
  • Helvaci MR, Abyad A, Pocock L. High and low density lipoproteins may be negative acute phase proteins of the metabolic syndrome. Middle East J Nursing 2020; 14(1): 10-16.
  • Helvaci MR, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Effects of sickle cell diseases on physical and metabolic parameters. Middle East J Intern Med 2020; 12(1): 4-9.
  • Helvaci MR, Arslanoglu Z, Abyad A, Pocock L. Sickle cell diseases are precirrhotic conditions. Middle East J Intern Med 2020; 12(1): 10-16.
  • Helvaci MR, Arslanoglu Z, Davran R, Duru M, Abyad A, Pocock L. Some signals of death in sickle cell diseases. Middle East J Intern Med 2020; 12(1): 17-21.
  • Helvaci MR, Arslanoglu Z, Davran R, Duru M, Abyad A, Pocock L. Deaths in sickle cell diseases may not be sudden unexpected events. Middle East J Intern Med 2020; 12(1): 22-28.
  • Helvaci MR, Aydin Y, Aydin LY, Abyad A, Pocock L. High density lipoproteins may act in a similar direction with low density lipoproteins in the metabolic syndrome. Middle East J Intern Med 2020; 13(1): 13-18.
  • Helvaci MR, Abyad A, Pocock L. Low density lipoproteins may actually be some negative acute phase proteins in the plasma. Middle East J Intern Med 2020; 13(1): 19-24.
  • Helvaci MR, Aydin Y, Abyad A, Pocock L. Effects of thalassemia minor plus iron deficiency anemia on weight, height, and body mass index. Middle East J Intern Med 2020; 13(2): 29-33.
  • Helvaci MR, Sari I, Abyad A, Pocock L. Systemic disorders in the pathophysiology of rheumatic heart disease. Middle East J Intern Med 2020; 13(2): 34-38.
  • Helvaci MR, Yaprak M, Abyad A, Pocock L. Body weight and blood pressure. Middle East J Nursing 2020; 14(2): 22-27.
  • Helvaci MR, Duru M, Abyad A, Pocock L. Body weight and plasma lipoproteins. Middle East J Nursing 2020; 14(2): 28-34.
  • Helvaci MR, Yalcin A, Arslanoglu Z, Duru M, Abyad A, Pocock L. Prognostic significance of plasma bilirubin in sickle cell diseases. Middle East J Intern Med 2020; 13(3): 7-13.
  • Helvaci MR, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Triglycerides may be acute phase reactants which are not negatively affected by pathologic weight loss. Middle East J Intern Med 2020; 13(3): 14-19.
  • Helvaci MR, Salaz S, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Cholesterol may be a negative whereas triglycerides positive acute phase reactants in the plasma. Asclepius Med Res Rev 2021; 4(1): 1-8.
  • Helvaci MR, Duru M, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Body mass index may be the major determining factor of systolic and diastolic blood pressure in the human body. Middle East J Nursing 2021; 15(1): 12-17.
  • Helvaci MR, Yaprak M, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Body mass index may be the major determining factor of plasma cholesterol values. Middle East J Nursing 2021; 15(1): 18-24.
  • Helvaci MR, Yaprak M, Davran R, Arslanoglu Z, Abyad A, Pocock L. Worse prognosis of sickle cell diseases in males even in the absence of smoking and alcohol. Middle East J Nursing 2021; 15(2): 13-20.
  • Helvaci MR, Sevinc A, Camci C, Keskin A, Abyad A, Pocock L. Atherosclerotic background of cirrhosis in sickle cell patients. Middle East J Nursing 2021; 15(2): 21-25.
  • Helvaci MR, Yilmaz H, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. A much higher prevalence of chronic obstructive pulmonary disease in males with sickle cell diseases even in the absence of smoking and alcohol. Middle East J Intern Med 2021; 14(1): 10-16.
  • Helvaci MR, Arslanoglu Z, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Pulmonary hypertension may not have an atherosclerotic background in sickle cell diseases. Middle East J Intern Med 2021; 14(1): 17-25.
  • Helvaci MR, Yilmaz H, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Avascular necrosis may not have an atherosclerotic background in sickle cell diseases. Middle East J Nursing 2021; 15(3): 13-23.
  • Helvaci MR, Yilmaz H, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Autosplenectomy may not have an atherosclerotic background in sickle cell diseases. Middle East J Nursing 2021; 15(3): 24-33.
  • Helvaci MR, Yilmaz H, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Acute chest syndrome may not have an atherosclerotic background in sickle cell diseases. Middle East J Intern Med 2021; 14(2): 10-19.
  • Helvaci MR, Yilmaz H, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Sickle cell anemia versus sickle cell diseases in adults. Middle East J Intern Med 2021; 14(2): 20-26.
  • Helvaci MR, Salaz S, Altintas E, Muftuoglu OE, Abyad A, Pocock L. Irritable bowel syndrome is a multisystemic inflammatory disorder. Adv Res Gastroentero Hepatol 2022; 18(4): 555992.
  • Helvaci MR, Altintas E, Yaprak M, Davran R, Abyad A, Pocock L. Obesity may actually be a precirrhotic condition in adults. Middle East J Nursing 2022; 16(1): 20-26.
  • Helvaci MR, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Acute phase reactants in irritable bowel syndrome. Middle East J Nursing 2022; 16(1): 27-33.
  • Helvaci MR, Altintas E, Canda MS, Muftuoglu OE, Abyad A, Pocock L. Plasma triglycerides and fasting plasma glucose may behave as sensitive acute phase reactants in irritable bowel syndrome. Middle East J Age and Ageing 2022; 16(1): 7-13.
  • Helvaci MR, Altintas E, Yaprak M, Davran R, Abyad A, Pocock L. Umbilical hernia should alert physicians about terminal endpoints of the metabolic syndrome in adults. Middle East J Age and Ageing 2022; 16(1): 14-19.
  • Helvaci MR, Salaz S, Altintas E, Yalcin A, Abyad A, Pocock L. Smoking causes a low-grade systemic inflammation in human body. Middle East J Nursing 2022; 16(2): 16-22.
  • Helvaci MR, Altintas E, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Positive and negative acute phase reactants in smokers. Middle East J Nursing 2022; 16(2): 42-48.
  • Helvaci MR, Salaz S, Altintas E, Muftuoglu OE, Abyad A, Pocock L. Smoking may not increase systolic and diastolic blood pressures. 10.32474/OAJCAM.2022.04.000185.
  • Helvaci MR, Kayabasi Y, Celik O, Dede G, Abyad A, Pocock L. Irritable bowel syndrome is a multisystemic inflammatory disorder. Adv Res Gastroentero Hepatol 2022; 19(2): 556006.
  • Helvaci MR, Dede G, Celik O, Beray B, Abyad A, Pocock L. What a lower fasting plasma glucose in smokers. Adv Res Gastroentero Hepatol 2023; 19(2): 556007.
  • Helvaci MR, Ceylan A, Kayabasi Y, Sencan H, Abyad A, Pocock L. Smoking may not prevent overweight or obesity. EC Clinical and Medical Case Reports 2023; 6(2): 21-8.
  • Helvaci MR, Kayabasi Y, Celik O, Sencan H, Abyad A, Pocock L. Smoking causes a moderate or severe inflammatory process in human body. Am J Biomed Sci & Res 2023; 7(6): 694-702.
  • Helvaci MR, Kayabasi Y, Celik O, Dede G, Abyad A, Pocock L. Smoking increases triglycerides and low density lipoproteins in the plasma. PriMera Scientific Medicine and Public Health 2023; 2(3): 33-40.
  • Helvaci MR, Ozer AR, Candan E, Sahin I, Abyad A, Pocock L. Sickle cell diseases may show terminal consequences of the metabolic syndrome in much earlier ages. Mathews J Cytol Histol 2023; 7(1): 22.
  • Helvaci MR, Kayabasi Y, Celik O, Dede G, Abyad A, Pocock L. Fasting plasma glucose may initially behave as a positive but eventually negative acute phase reactant in the body. J Clin Stud Rev Rep 2023; 5(2): 1-7.
  • Helvaci MR, Kayabasi Y, Yalcin A, Muftuoglu OE, Abyad A, Pocock L. Smoking may not have a long term effect on body weight. J Hypertens Manag 2023; 9:074.
  • Helvaci MR, Kayabasi Y, Celik O, Dede G, Abyad A, Pocock L. What a low prevalence of diabetes mellitus in digital clubbing. Mathews J Diabetes Obes 2023; 6(1):15.
  • Helvaci MR, Kayabasi Y, Bahar B, Dede G, Abyad A, Pocock L. What a lower value of fasting plasma glucose in smokers. J Clinical Case Reports and Trails 2023; 2(1): DOI: 10.58489/2836-2217/CCRT.
  • Helvaci MR, Bastaci F, Aydin GY, Kucukbesleme HF, Abyad A, Pocock L. Lifelong aspirin even in childhood in sickle cell diseases. International Journal of Clinical Studies and Medical Case Reports. DOI: 10.46998/IJCMCR.2023.26.000642.
  • Helvaci MR, Candan E, Ceylan A, Sencan H, Abyad A, Pocock L. Depression causes various inflammatory processes in human body. Middle East J Nursing 2023; 17(1): 31-41.
  • Helvaci MR, Ozer AR, Candan E, Sahin I, Abyad A, Pocock L. Corticosteroids during acute painful crises of sickle cell diseases. Biomed J Sci & Tech Res 2023; 50(3): 41684-94.
  • Helvaci MR, Tuncsezen UK, Seckin K, Piral K, Seyhan S, Karabacak AD, Camlibel M, Abyad A, Pocock L. An exaggerated capillary endothelial edema-induced myocardial infarction or stroke may be the cause of sudden deaths in sickle cell diseases. J Clin Res Case Stud 2023; 1(2): 1-11.
  • Helvaci MR, Pappel V, Piral K, Ozer S, Camlibel M, Sencan H, Davran R, Abyad A, Pocock L. As a good prognostic sign, autosplenectomy is higher in females in sickle cell diseases. Middle East J Nursing 2023; 17(2): 24-38.
  • Helvaci MR, Pappel V, Piral K, Ozer S, Camlibel M, Sencan H, Davran R, Abyad A, Pocock L. Male gender alone may be a bad prognostic factor in sickle cell diseases. Middle East J Nursing 2023; 17(2): 39-52.
  • Helvaci MR, Pappel V, Piral K, Ozer S, Camlibel M, Sencan H, Davran R, Abyad A, Pocock L. Red blood cell supports prolong the survival in sickle cell diseases. Middle East J Nursing 2023; 17(2): 53-66.
  • Helvaci MR, Pappel V, Piral K, Caylar A, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of stroke in sickle cell diseases. Sci Set J of Cardiology Res 2023; 2(3): 01-14.
  • Helvaci MR, Pappel V, Piral K, Caylar A, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of chronic renal disease in sickle cell diseases. Journal of Gynecology and Reproductive Health 2023; 1(1): 01-14.
  • Helvaci MR, Pappel V, Piral K, Camlibel M, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Low-dose aspirin plus low-dose warfarin may be life-saving treatment regimens in cases with severe chronic obstructive pulmonary disease. Biomed J Sci and Tech Res 2023; 53(2). BJSTR.MS.ID.008382.
  • Helvaci MR, Pappel V, Piral K, Camlibel M, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Acute edematous background of leg ulcers in arterial endothelium in sickle cell diseases. Ame J Surg Clin Case Rep 2023; 7(2): 1-15.
  • Helvaci MR, Pappel V, Piral K, Camlibel M, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Male gender alone may be a bad prognostic feature in sickle cell diseases. Int J of Diabetes its Complications 2023; 1(1): 1-14.
  • Helvaci MR, Pappel V, Piral K, Caylar A, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of digital clubbing in sickle cell diseases. Middle East J Nursing 2023; 17(3): 14-28.
  • Helvaci MR, Pappel V, Piral K, Camlibel M, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of chronic obstructive pulmonary disease in sickle cell diseases. Universal Library of Medical and Health Sciences 2023; 1(1): 1-15.
  • Helvaci MR, Pappel V, Arslanoglu Z, Caylar A, Sencan H, Davran R, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of disseminated teeth losses in sickle cell diseases. Journal of Clinical Case Studies, Reviews and Reports 2023; 1(2): 01-17.
  • Helvaci MR, Alrawii I, Camci C, Sevinc A, Nisa EK, Ersahin T, Atabay A, Abyad A, Pocock L. What a higher prevalence of thalassemias in cases without tonsilectomy in sickle cell diseases. Biomed J Sci and Tech Res 2024; 54(4). DOI: 10.26717/BJSTR.2024.54.008596.
  • Helvaci MR, Camci C, Sevinc A, Nisa EK, Ersahin T, Atabay A, Davran R, Abyad A, Pocock L. Prolonged tonsillar hypertrophy may be an indicator of disease-induced immunosuppression in sickle cell patients. Middle East J Nursing 2023; 18(1): 13-28.
  • Helvaci MR, Camci C, Nisa EK, Ersahin T, Atabay A, Alrawii I, Ture Y, Abyad A, Pocock L. Severity of sickle cell diseases restricts smoking. Ann Med Medical Res 2024; 7: 1074.
  • Helvaci MR, Cayir S, Halici H, Sevinc A, Camci C, Sencan H, Davran R, Abyad A, Pocock L. Acute chest syndrome and coronavirus disease may be genetically determined exaggerated immune response syndromes in capillaries all over the body. International Journal on Allergy and Immunology 2024; 2(2): 1-9.
  • Helvaci MR, Cayir S, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Red blood cell transfusions may have the strongest analgesic effect during acute painful crises in sickle cell diseases. Ann Clin Med Case Rep 2024; V13(12): 1-12.
  • Helvaci MR, Cayir S, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Chronic inflammatory processes may prevent malignancies. Ann Clin Med Case Rep 2024; V13(17): 1-12.
  • Helvaci MR, Daglioglu MC, Halici H, Sen C, Sevinc A, Camci C, Abyad A, Pocock L. Anti-inflammatory dose of aspirin plus low-dose warfarin in addition to hydroxyurea may be the optimal treatment regimen of leg ulcers in sickle cell diseases. Biomed J Sci and Tech Res 2024; 57(2). BJSTR.MS.ID.008976.
  • Helvaci MR, Yilmaz TS, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Biological ages of sickle cell patients. Ann Clin Med Case Rep 2024; V14(4): 1-13.
  • Helvaci MR, Yilmaz TS, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Metformin in the treatment of chronic obstructive pulmonary disease even in cases with normal weight. Ann Clin Med Case Rep 2024; V14(6): 1-14.
  • Helvaci MR, Kurt GD, Halici H, Erdogan K, Sevinc A, Camci C, Abyad A, Pocock L. Metformin in the treatment of coronary heart disease. J Biotechnol Bioinforma Res 2024; 6(5): 1-12.
  • Helvaci MR, Kurt GD, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Metformin in prevention of stroke. J Gastro Hepato 2024; V10(14): 1-14.
  • Helvaci MR, Halici H, Erdogan K, Albayrak M, Sevinc A, Camci C, Abyad A, Pocock L. Chronic idiopathic purpura may even prolong survival in human being in general. J Cur Tre Clin Case Rep 2025; 6(4): 1-6.
  • Helvaci MR, Halici H, Erdogan K, Sevinc A, Camci C, Abyad A, Pocock L. Acarbose in the treatment of coronary heart disease. Clinical Case Reports and Clinical Study 2025; 12(1): DOI: 10.61148/2766-8614/JCCRCS/200.
  • Helvaci MR, Halici H, Erdogan K, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Acarbose in the treatment of cirrhosis. J Gastro Endosc 2025; 3(2): 1-13.
  • Helvaci MR, Halici H, Kurt GD, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Acarbose in prevention of stroke. Clinical Research in Hematology 2025; 5(1): DOI.ORG/10.33309/2639-8354.050101
  • Helvaci MR, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Acarbose in the treatment of chronic renal disease. Clinical Case Reports and Case Studies. AmeriRead Publishers. 2025; 1(5): DOI: 10.61148/3067-0209.ccrcs.25.030
  • Helvaci MR, Helvaci E, Kamalak IS, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Acarbose should be the first-line antidiabetic agent. Journal of Clinical Case Reports, Medical Images and Health Sciences 2025; 12(3): DOI: 10.55920/JCRMHS.2025.12.001540
  • Helvaci MR, Helvaci E, Kamalak IS, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Excess fat tissue may be the most significant atherosclerotic risk factor in the body. International Journal of Clinical Cardiology and Cardiovascular Interventions 2025; 5(1): DOI: 10.61148/2836-2837/IJCCCI/0221.
  • Helvaci MR, Helvaci E, Helvaci E, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Weight loss with acarbose and metformin may be curative in early phases of diabetes mellitus. J Clin Gastro Hepatol Res 2025; 7(2): 150
  • Helvaci MR, Helvaci E, Helvaci E, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. Diabetes mellitus may actually be one of the atherosclerotic endpoints in whole body rather than the pancreas alone. World J Radiolo Img 2025; 4(4): 1-16.
  • Helvaci MR, Helvaci E, Helvaci E, Aydin Y, Aydin LY, Sevinc A, Camci C, Abyad A, Pocock L. The term of excess weight should be replaced with excess fat tissue in human body. Adv Res Gastroentero Hepatol 2025; 22(1): ARGH.MS.ID.556078
  • Helvaci MR, Ozcan A. White coat hypertension is a pioneer sign of metabolic syndrome. J Metabolic Synd 2015; 4: 172.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Yaprak M, Abyad A, Pocock L. Aging syndrome. World Family Med 2017; 15(3): 39-42.
  • Helvaci MR. Sickle cell diseases as an accelerated atherosclerotic process in whole body including the heart. EC Cardiology 2017; 3(4): 128-133.
  • Helvaci MR, Kuvandik G, Kaya H, Ozer B, Irde H and Yetim T. Such High Prevalences of Thyroidectomy Operations Should Be Restricted. Journal of Medical Sciences 2007; 7: 1073-1075.
  • Helvaci MR, Ayyildiz O, Muftuoglu OE, Yaprak M, Abyad A, Pocock L. Academicianship. World Family Med 2017; 15: 34-35.
  • Helvaci MR. Middle East J Intern Med 2020; 12: Supplementary issue.
  • Helvaci MR. Hepatitis C virus infection may always terminate with chronic manifestations of it if life span of the human being would be enough. Poster presentation at the 46th annual conference of the Indian Society of Gastroenterology 2005, Serial No: LV 23.
  • Helvaci MR, Ozer C, Algin MC, Kaya H, Kuvandik G. A Physiologic Events’ Cascade, Irritable Bowel Syndrome, May Even Terminate with Chronic Gastritis. European General Practice Research Network, Presentation 41, Antalya – Turkey, 8th – 11th May, 2008.
  • Helvacı MR, Özkan OV, Duran N, Topaloğlu C, Bal ME, Görgel A. Irritable bowel syndrome and body mass index. Hepato-Gastroenterology 55; 2008: P 504.
  • Helvacı MR, Borazan A, Özkan OV, Uçar E, Değirmenci VG. Cholelithiasis and parameters of physical health. Hepato-Gastroenterology 55; 2008: P 003.
  • Kuvandık G, Helvacı MR, Özkan OV, Söğüt S, Kaya H. Is there any significant association between irritable bowel syndrome and cholelithiasis? Hepato-Gastroenterology 55; 2008: P 004.
  • Gökçe A, Davarcı M, Yalçınkaya FR, Güven EO, Kaya YS, Helvacı MR, Balbay MD. Hereditary behavior of varicocele. EAU 3rd North Eastren European Meeting (NEEM).
  • Motor S, Ulutaş KT, Can Y, Erduran R, Yönden Z, Büyükbaş S, Helvacı R. Assesment of hematologic parameters in sickle cell disorders in South region of Turkey. SCDAA 40th Anniversary Convention 2012.
  • Helvaci MR. White coat hypertension may actually be an acute phase reactant in the body. 3rd International Conference on Hypertension and Healthcare. August 24-25, 2018, Tokyo, Japan.
  • Kaya H, Helvaci MR, Ustun I, Gokce C, Çelik MN, Ucar E. P-47 LDL-APHERESIS IN FAMILIAL HYPERCHOLESTEROLEMIA (FH). Transfusion and Apheresis Science 2012; P-47: S43.
  • Kaya H, Helvaci MR, Ucar E, Çelik MN. P-40 AUTOMATED ERYTHROCYTE EXCHANGE (AEE) EXPERIENCE OF APHERESIS UNIT IN MUSTAFA KEMAL UNIVERSITY SCHOOL OF MEDICINE FOR SICKLE CELL DISEASE (SCD). Transfusion and Apheresis Science 2012; P-47(1): S40.
  • Helvaci MR, Ari M, Maden E, Aydin LY, Aydin Y, Ozer C. Effects of season-induced hormonal changes on mortality. World Family Med 2012; 10(8).
  • Helvaci MR, Abyad A, Pocock L. The lowest is the safest value of plasma triglycerides. World Family Med 2019; 17(10).
  • Helvacı MR. Importance of antithyroglobulin antibody for the diagnosis of autoimmune thyroiditis. Haydarpaşa Numune Hastanesi Tıp Dergisi 2005; 45: 135-137.
  • Helvacı MR, Dayıoğlu H, Algın MC, Coşar E, Soyucen E. Hepatitis C virus infection may always terminate with chronic manifestations of it if life span of the human being would be enough. Dumlupınar Üniversitesi Fen Bilimleri Enstitüsü Dergisi 2005; 9: 187-194.
  • Gülcan E, Helvacı MR, Bıcık Z, Özcura F, Gülcan A. Relationship between renal functions and C reactive protein in overweight and obese subjects without diabetes mellitus and hypertension. Endokrinolojide Yönelişler 2006; 15: 6-12.
  • Özcura F, Helvacı MR, Aydın S, Gülcan E. Tip 2 diabetes mellituslu hastalarda diabetik retinopati prevalansı. Endokrinolojide Yönelişler 2006; 15: 98-103.
  • Helvacı MR, Altıntaş E, Yalçın A. Suspected relationship between chronic hepatitis C and autoimmune thyroiditis may actually be a result of already existing high prevalence of autoimmune thyroiditis in society. Endokrinolojide Yönelişler 2006; 15: 130-134.
  • Helvacı MR, Gülcan E, Özcura F, Şahin L, Elem E, Öztürk S. Obesity is not less frequent in Turkey than in developed countries. Endokrinolojide Yönelişler 2006; 15: 170-173.
  • Helvacı MR, Coşar E, Soyuçen E, Şahin L. Prevalence of smoking does not change in normal weight, overweight, and obese individuals. Endokrinolojide Yönelişler 2007; 16: 31-35.
  • Helvacı MR, Özcura F, Güllü M, Yetim T, Bal ME, Hüzmeli C. Relationship Between Excess Weight and Cataract Among Turkish Population: A Retrospective Case-Controlled Study. Endokrinolojide Yönelişler 2007; 16: 55-59.
  • Helvacı MR, Özcura F, Soyuçen E, Şahin L, Öztürk S, Elem E. Body mass index is related with physical but not mental health. Endokrinolojide Yönelişler 2007; 16: 122-127.
  • Helvacı MR, Kaya H, Balcı A, Özkan OV. Relationship between body mass index and diaphragmatic eventrations. Endokrinolojide Yönelişler 2007; 16: 170-173.
  • Helvacı MR, Özkan OV, Duran N, Topaloğlu C, Bal ME, Görgel A. Irritable bowel syndrome and body mass index. Endokrinolojide Yönelişler 2008; 17: 50-53.
  • Özkan OV, Helvacı MR, Gökçe C, Ardaman Ö, Budak A, Duru M, Semerci E. Tiroidektomi vakalarında otoimmün tiroidit prevalansı. Endokrinolojide Yönelişler 2008; 17: 54-56.
  • Helvacı MR, Güllü M, Kaya H, Özkan OV, Balcı A, Uçar E. What a high prevalence of thyroid nodules in women! Journal of Dialog in Endocrinology 2008; 2: 33-37.
  • Helvacı MR, Savaş N, Gökçe C, Görgel A, Değirmenci VG. Body mass index and serum alanine aminotransferase value. Endokrinolojide Yönelişler 2008; 17: 119-122.
  • Kuvandık G, Helvacı MR, Özkan OV, Söğüt S, Kaya H, Bozkurt S. Is there any significant association between irritable bowel syndrome and cholelithiasis? Akademik Acil Tıp Dergisi 2008; 7: 28-30.
  • Gökçe A, Helvacı MR, Özkan OV, Kaya H. Obesity and primary premature ejaculation. Endokrinolojide Yönelişler 2008; 17: 159-162.
  • Gökçe A, Helvacı MR, Özkan OV, Rızaoğlu H, Kaya YS, Kaya H. Body weight and urolithiasis. Endokrinolojide Yönelişler 2009; 18: 13-16.
  • Özkan OV, Yetim İ, Semerci E, Davran R, Helvacı MR, Ardaman Ö, Budak A. Multinodüler guatrlı hastalarda nodül çaplarının ultrasonografi ve makroskopik patolojik inceleme yöntemleriyle ölçümünün karşılaştırılması. Endokrinolojide Yönelişler 2009; 18: 2-7.
  • Gökçe A, Helvacı MR, Savaş N, Özkan OV, Kaya YS, Kaya H. Body mass index and secondary premature ejaculation. Endokrinolojide Yönelişler 2009; 18: 8-12.
  • Özkan OV, Helvacı MR, Gökçe A, Kaya E, Kaya YS, Kaya H. Body weight and chronic gastritis. Endokrinolojide Yönelişler 2009; 18: 66-70.
  • Doğramacı AÇ, Yenin JZ, Havlucu DY, Helvacı MR. Akrokordon bozulmuş karbonhidrat metabolizması ile ilişkili mi? Türkiye Klinikleri Dermatoloji Dergisi 2009; 19: 125-128.
  • Helvacı MR, Savaş N, Aydın M, Kaplan A, Doğramacı AÇ, Kaya H. Decreased physical activity may be the main cause of excess weight and its complications in elder individuals. Endokrinolojide Yönelişler 2009; 18: 118-121.
  • Helvacı MR, Davarcı M, Özkan OV, Semerci E, Kaplan A, Değirmenci VG. Cholelithiasis and Parameters of Physical Health. Endokrinolojide Yönelişler 2009; 18: 122-126.
  • Öztürk OH, Ulutaş KT, Helvacı MR, Kurtgöz ÖY, Okumuş N, Aydın M, Yönden Z. Mustafa Kemal Üniversitesi Tıp Fakültesi Hastanesine başvuran sağlıklı bireylerin lipid profili analizinde yaş ve cinsiyetin rolü. Endokrinolojide Yönelişler 2009; 18: 127-130.
  • Helvacı MR, Davarcı M, Meydan S, İnci M, Çelik MM, Al M. Body mass and varicocele. Endokrinolojide Yönelişler 2009; 18: 186-190.
  • Davarcı M, Helvacı MR, Karcıoğlu M, Aydın M, Arslan MM. Urolithiasis and parameters of physical health. Endokrinolojide Yönelişler 2009; 18: 191-195.
  • Helvacı MR, Özkan OV, Meydan S, Çelik MM, Çelik S, Cezgin K. Body mass and inguinal hernia. Endokrinolojide Yönelişler 2010; 19: 11-15.
  • Helvacı MR, Özkan OV, Meydan S, Çelik S, Ertekin F, Dikmen N. Body mass and umbilical hernia. Endokrinolojide Yönelişler 2010; 19: 16-21.
  • Helvacı MR, Arıca V, Tutanç M, Keskin A. Metabolic syndrome even in children. Endokrinolojide Yönelişler 2010; 19: 38-42.
  • Helvacı MR, Özkan OV, Kaya H. Canda MŞ. Reversible components and terminal consequences of the metabolic syndrome. Endokrinolojide Yönelişler 2010; 19: 58-63.
  • Helvacı MR, İlhan Ö, Kaya H, Canda MŞ. Despite limited benefit, funduscopic examination should be continued for hypertension. Mustafa Kemal Üniversitesi Tıp Fakültesi Dergisi 2010; 1 (2): 1-5.
  • Helvacı MR, Davran R, Çelik S, Al M, Ertekin F, Cezgin K. Body mass and fasting plasma glucose. Endokrinolojide Yönelişler 2010; 19: 98-101.
  • Helvacı MR, Albayrak M, Balçık ÖŞ, Çelebi H, Ertekin F. Hematocrit value and body mass index. Endokrinolojide Yönelişler 2010; 19: 130-133.
  • Helvacı MR, Oktar S, Günay FY, Tellioğlu MÖ, Arıca F, Kaya H. What a high frequency of deferiprone-induced agranulocytosis in a Turkish population of thalassemia major. Mustafa Kemal Üniversitesi Tıp Fakültesi Dergisi 2011; 2: 17-27.
  • Helvacı MR, Arı M, Aydoğan A, Algın MC, Maden E. Body mass index in alpha thalassemias. Endokrinolojide Yönelişler 2010; 19: 163-167.
  • Arı M, Üstün İ, Helvacı MR. Obezitede ailesel işlevlerde değişiklikler. Endokrinolojide Yönelişler 2011; 20: 8-13.
  • Yılmaz N, Öztürk OH, Genç M, Yönden Z, Helvacı MR, Yılmaz M, Ulutaş KT. Orak hücre anemisiyle lipid profilinin ilişkisi. Endokrinolojide Yönelişler 2011; 20: 19-22.
  • Helvacı MR, Maden E, Aydın LY, Aydın Y. Chronic obstructive pulmonary disease and metabolic syndrome. Endokrinolojide Yönelişler 2011; 20: 34-39.
  • Albayrak M, Helvacı MR, Selçuk NY, Çetinkaya R, Odabaş AR, Gündoğdu M. Effects of amlodipine, fosinopril and losartan on proteinuria in nephropathy patients with type 2 diabetes mellitus. Diabet Bilimi 2011; 9: 231-236.
  • Helvacı MR, Önder Hİ, Erbilen E, Bilen A. A Plasmacytoma Presenting as A Right-Sided Retroorbital Mass. Düzce Tıp Fakültesi Dergisi 2004; 3: 23-25.
  • Coşar E, Helvacı MR. A multicystic ultrasonographic image of endometrium in tamoxifen use; case report. Dumlupınar Üniversitesi Fen Bilimleri Enstitüsü Dergisi 2006; 10: 181-183.
  • Arı M, Şilfeler DB, Gökçe C, Üstün İ, Görgel A, Dolapçıoğlu KS, Öztürk OH, Bayaroğulları H, Helvacı MR. Depresyonla birliktelik gösteren hirsutizmli bir olgu. Endokrinolojide Yönelişler 2010; 19: 134-137.
  • Yetim İ, Yetim TD, Özkan OV, Diner G, Savaş N, Davran R, Helvacı R, Kaya H. Bilateral primary breast lymphoma: A rare case. The Journal of Breast Health 2011; 7: 185-187.
  • Akçay AB, Bilen P, Kavvasoğlu B, Helvacı R, Yalçın F. İlk klinik bulgusu akut perikardit olan akut lösemi olgusu. Kardiyoloji 2011; 18: 226-227.
  • Aydoğan F, Yengil E, Üstün N, Özden R, Helvacı MR. Orak hücre anemi krizine sekonder bilateral femur başı osteonekrozunun kemik sintigrafisi ile değerlendirilmesi. Mustafa Kemal Üniversitesi Tıp Fakültesi Dergisi 2012; 3: 47-51.
  • Şen BB, Rifaioğlu EN, Ekiz Ö, Yaldız M, Helvacı MR, Doğramacı AÇ. Cutaneous involvement in multiple myeloma: A case report. Abant Med J 2014; 3: 274-276.
  • Helvacı MR, Karakaya B. Otoimmün Tiroidit. Endokrinolojide Yönelişler 2006; 15: 122-128.
  • Özcura F, Helvacı MR. Diabetik Retinopati ve Medikal Tedavisi. Türkiye Klinikleri Oftalmoloji Dergisi 2006; 15: 132-139.
  • Cımbız A, Özyurt MS, Dayıoğlu H, Helvacı MR, Yılmaz H. Bitki özütlerinin stres, hiperglisemi, hiperlipidemi üzerine etkileri. Dumlupınar Üniversitesi Fen Bilimleri Enstitüsü Dergisi 2005; 9: 1-14.
  • Dayıoğlu H, Özyurt MS, Helvacı MR, Solak CN. Türkiye’de tavuk vebası (Kuş gribi). Dumlupınar Üniversitesi Fen Bilimleri Enstitüsü Dergisi 2006; 10: 1-14.
  • Tutanç M, Helvacı MR, Başarslan F, Akçay B. Çocuklarda kilo ve metabolik sendrom. Endokrinolojide Yönelişler 2011; 20: 40-45.
  • Çelik S, Helvacı MR, Altan A, Kılınç AE. Halitozis ve metabolik sendrom. Diabet Bilimi 2011; 9: 254-258.
  • Helvacı MR, Aydın Y, Aydın LY, Maden E. Metabolic syndrome. Endokrinolojide Yönelişler 2011; 20: 71-76.
  • Helvaci MR. Orak hücre hastalıkları. Mustafa Kemal Üniversitesi Tıp Dergisi 2015; 22: 25-34.
  • Helvacı MR, Albayrak M. Orak hücre hastalıkları. Turkiye Klinikleri J Hematol-Special Topics 2016; 9(3): 40-46.
  • Özcura F, Helvacı MR, Aydın S, Gülcan E. Tip 2 diabetes mellituslu hastalarda diabetik retinopati prevalansı. 40. Ulusal Oftalmoloji Kongresi 2006, P-TR-097, Antalya.
  • Helvacı MR, Öztürk K. Tedaviye dirençli gebelik immun trombositopenik purpurasında intravenöz anti-D immunoglobulinin etkinliği. 33. Ulusal Hematoloji Kongresi 2007, P246, Ankara.
  • Helvacı MR, Günay FY, Kaya H, Tellioğlu MÖ, Yalçın A. Türk talasemi majör hastalarında deferiprona bağlı agranülositozun sıklığı. 33. Ulusal Hematoloji Kongresi 2007, P50, Ankara.
  • Helvacı MR, Kaya H, Yalçın A. Miyelodisplastik sendromda siklosporin’in etkinliği. 33. Ulusal Hematoloji Kongresi 2007, P107, Ankara.
  • Helvacı MR, Kaya H, Seyfeli E, Güllü M, Tekiş İZ, Karakaş CY. Akut endokardit ile komplike olan carbamazepin’e bağlı hemolitik anemi. 33. Ulusal Hematoloji Kongresi 2007, P62, Ankara.
  • Helvacı MR, Kaya H, Bal ME. Sağ taraf retroorbital plazmositom. 33. Ulusal Hematoloji Kongresi 2007, P200, Ankara.
  • Helvacı MR, Kaya H, Görgel A, Değirmenci VG, Kaya E, Gümüş R. Ağrılı krizler ile akut tonsilitin sık birlikteliği. 34. Ulusal Hematoloji Kongresi 2008, P0102, İzmir.
  • Kaya H, Helvacı MR, Önlen Y, Görgel A, Güllü M. İnsanda erlişiyoz. 34. Ulusal Hematoloji Kongresi 2008, P0068, İzmir.
  • Helvacı MR, Kaya H, Değirmenci VG. Akselere faz kronik miyeloid lösemide nilotinib. 34. Ulusal Hematoloji Kongresi 2008, P0183, İzmir.
  • Uçar E, Çetin M, Kuvandik C, Asilyörük S, Güllü M, Helvacı MR. Hatay bölgesinde hemodiyaliz hastalarında hepatit E virüs sıklığı. Onuncu Ulusal İç Hastalıkları Kongresi 2008, P209, Antalya.
  • Uçar E, Helvacı MR, Yetim T, Değirmenci VG, Semerci E, Tekiş İ, Öztürk K. Hemodiyaliz hastalarında gastrointestinal lezyonlar ve Helikobakter pylori sıklığı. Onuncu Ulusal İç Hastalıkları Kongresi 2008, P083, Antalya.
  • Özkan OV, Helvacı MR, Gökçe A, Kaya E, Kaya YS, Kaya H. Vücut ağırlığı ve kronik gastrit. 3. Uludağ Üniversitesi Genel Cerrahide Güncel Yaklaşımlar Toplantısı, 5-8 Mart 2009, Bursa, P-9.
  • Yönden Z, Kurt ÖY, Okumuş N, Öztürk OH, Ulutaş KT, Helvacı R, Aydın M. Mustafa Kemal Üniversitesi Tıp Fakültesi’ne Başvuran Hastaların Lipid Profili Analizinde Yaş ve Cinsiyetin Rolü. 9. Ulusal Klinik Biyokimya Kongresi 2009, P-86, Antalya.
  • Helvacı MR, Kaya H, Ulutaş KT, Duman İ, Etcibaşı Ş. Seksen yaşında bir erkek hastada kazanılmış hemofili. 35. Ulusal Hematoloji Kongresi 2009, P-33, Antalya.
  • Helvacı MR, Doğramacı ÇA, Duman İ, Değirmenci VG, Ulutaş KT, Canda MŞ. Doksan yaşında bir bayan hastada yeni tanı von Willebrand tip 2B. 35. Ulusal Hematoloji Kongresi 2009, P-48, Antalya.
  • Helvacı MR, Kaya H, Duman İ, Öztürk OH, Ulutaş KT. Orak hücreli anemisi ile hepatit C virüs enfeksiyonunun sık birlikteliği. 35. Ulusal Hematoloji Kongresi 2009, P-160, Antalya.
  • Helvacı MR, Arıca V, Tutanç M, Kaya H, Keskin A. Çocuklarda metabolik sendrom temelini düşündüren bulgular. 46. Türk Pediatri Kongresi 2010, P144, Çeşme, İzmir.
  • Yokuş O, Yılmaz B, Albayrak M, Balçık ÖŞ, Helvacı MR, Sennaroğlu E. Kronik hastalık anemisine eşlik eden demir eksikliğini tespit etmede serum transferrin reseptör düzeyinin önemi. 1. Avrasya Hematoloji Kongresi 2010, P22, Antalya.
  • Helvacı MR, Kaya H, Rızaoğlu H, Ertekin F, Kavvasoğlu GH. Orak hücre hastalıklarında çoğu zaman mortaliteyi tek bir sebebe bağlamak oldukça güçtür. 36. Ulusal Hematoloji Kongresi 2010, P117, Antalya.
  • Helvacı MR, Çelik S. Orak hücre hastalıklarında belirgin gelişme geriliği. 36. Ulusal Hematoloji Kongresi 2010, P104, Ref. No: 0122, Antalya.
  • Helvacı MR, Kaya H. Alfa talasemi vakalarında vücut kitle endeksi. 37. Ulusal Hematoloji Kongresi 2011, P112, Ankara.
  • Helvacı MR, Kaya H, Eraslan S. Orak hücre hastalığında romatizmal kalp kapak hastalığının sıklığı. 37. Ulusal Hematoloji Kongresi 2011, P130, Ankara.
  • Helvacı MR, Kaya H, Demetgül Ö. Orak hücre hastalığında kronik tıkayıcı akciğer hastalığının sıklığı. 37. Ulusal Hematoloji Kongresi 2011, P129, Ankara.
  • Helvacı MR, Babayiğit C, Dolapçıoğlu K. Orak hücre hastalığında görülen klinik bulguların sıklığı. 37. Ulusal Hematoloji Kongresi 2011, P113, Ankara.
  • Helvacı MR, Kaya H, Mansuroğlu EY. Orak hücre hastalığında bacak yarasının erkeklerdeki sıklığı. 37. Ulusal Hematoloji Kongresi 2011, P114, Ankara.
  • Helvacı MR, Kaya H, Demetgül Ö. Orak hücre hastalığı ve çomaklaşma. 37. Ulusal Hematoloji Kongresi 2011, P118, Ankara.
  • Helvacı MR, Kaya H, Mansuroğlu EY. Orak hücre hastalığı ağrılı krizde hidroksiüre toksisitesi. 37. Ulusal Hematoloji Kongresi 2011, P138, Ankara.
  • Akçay AB, Şen N, Bilen P, Güngör M, Kesici TT, Öfgeli M, Kavvasoğlu B, Ertekin F, Helvacı R, Yalçın F, Kaya H. Talasemi majör hastalarında fragmente QRS ile sistolik ve diyastolik doku Doppler parametreleri arasındaki ilişki. 27. Ulusal Kardiyoloji Kongresi 2011, P-352, İstanbul.
  • Helvacı MR, Arı M, Gündoğdu M. Vücut kitle endeksi ve antisosyal kişilik bozukluğu. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): I.
  • Helvacı MR, Kaya H, Ayyıldız O, Gündoğdu M. Şişmanlık metabolik sendromun geri dönüşümsüz nihai hastalıklarından birisi olarak kabul edilmelidir. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): III.
  • Helvacı MR, Arı M, Maden E, Aydın LY, Aydın Y, Özer C. Mevsimsel hormonal değişikliklerin ölüm üzerine muhtemel etkileri. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): IV.
  • Helvacı MR, Özcura F, İnci M. Metabolik sendrom ve katarakt. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): V.
  • Helvacı MR, Maden E, Aydın LY, Aydın Y. Kronik tıkayıcı akciğer hastalığı ve metabolik sendrom. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): VI.
  • Helvacı MR, Algın MC, Özdoğu H. Hepatit C enfeksiyonunda karaciğer dışı tutulum. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): VII.
  • Helvacı MR, Kaya H, Öztürk OH. Fiziksel ve zihinsel aktivite ve gerilimler kan yağlarının ana belirleyici etkeni olabilir. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): VIII.
  • Helvacı MR, Aydın LY, Maden E, Aydın Y. Çomaklaşma ve metabolik sendrom. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): IX.
  • Helvacı MR, Özcura F, Akın MM. Beyaz önlük hipertansiyonunda göz dibi bulguları. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): X.
  • Helvacı MR, Özcura F, Kaya H. Arkus kornea dislipidemi tanısında sınırlı faydaya sahiptir. 2. Multidisipliner Aile Hekimliği Kongresi (18-20 Mayıs 2012) Bildirileri. Konuralp Tıp Dergisi 2012; 4(2): XII.
  • Helvacı MR, Kaya H, Batmacı CY. Ağrılı kriz göstermeyen orak hücre vakaları. 38. Ulusal Hematoloji Kongresi 2012, P-176, Antalya.
  • Helvacı MR, Kaya H, Cezgin K. Megaloblastik anemide belirgin kilo kaybı. 38. Ulusal Hematoloji Kongresi 2012, P-167, Antalya.
  • Helvacı MR, Kaya H, Çiğdem HÇ. Talasemi minör ve megaloblastik anemi birlikteliği. 38. Ulusal Hematoloji Kongresi 2012, P-178, Antalya.
  • Helvacı MR, Kaya H, Varan G. Orak hücre ağrılı krizde ilaçların karaciğer ve safra yolları toksisitesi. 38. Ulusal Hematoloji Kongresi 2012, P-174, Antalya.
  • Helvacı MR, Kaya H, Coşkun M. Orak hücre hastalığı kılcal damar ağını etkileyen hızlanmış bir ateroskleroz kliniğidir. 38. Ulusal Hematoloji Kongresi 2012, P-179, Antalya.
  • Helvacı MR, Coşkun M, Ağır YO. Orak hücre hastalığı şiddetli ağrılı krizlerinde eritrosit süspansiyonu transfüzyonunun önemi. 38. Ulusal Hematoloji Kongresi 2012, P-177, Antalya.
  • Helvacı MR, Kaya H, Çiğdem HÇ. Orak hücre hastalığı ve hepatit B ve C virüs enfeksiyonu. 38. Ulusal Hematoloji Kongresi 2012, P-169, Antalya.
  • Helvacı MR, Kaya H, Duman İ. Orak hücre hastalığında hidroksiüre. 38. Ulusal Hematoloji Kongresi 2012, P-159, Antalya.
  • Helvacı MR, Kaya H, Ağır YO. Orak hücre hastalığında talasemi birlikteliği. 38. Ulusal Hematoloji Kongresi 2012, P-173, Antalya.
  • Helvacı MR, Kaya H, Şimşek Ş. Orak hücre ve kronik parankimal karaciğer hastalıkları. 38. Ulusal Hematoloji Kongresi 2012, P-168, Antalya.
  • Şen BB, Rifaioğlu EN, Ekiz Ö, Yaldız M, Helvacı MR, Doğramacı AÇ. Multiple myeloma deri tutulumu. 24. Ulusal Dermatoloji Kongresi 2012, P-089, Gaziantep.
  • Helvacı MR, Motor S. Sigara içmeyen orak hücre hastalarında cinsiyete göre hastalığın şiddeti. 39. Ulusal Hematoloji Kongresi 2013, P-138, Antalya.
  • Helvacı MR, Davran R, Aslan Ö, Kurt A. Splenomegali zemininde gelişen sol böbrek atrofisi. 39. Ulusal Hematoloji Kongresi 2013, P-158, Antalya.
  • Helvacı MR, Davran R, Davarcı M, Turgutoğlu K. Orak hücre vakalarında sol böbrek atrofisi. 39. Ulusal Hematoloji Kongresi 2013, P-108, Antalya.
  • Helvacı MR, Aydın Y, Ayyıldız O, Turgutoğlu K. Hidroksiüre orak hücre hastalarının sağkalımını uzatan bir tedavi yaklaşımı olabilir. 39. Ulusal Hematoloji Kongresi 2013, P-112, Antalya.
  • Helvacı MR, Aslan Ö, Kurt A, Varan G, Batmacı CY. Orak hücre hastalarında hidroksiüre tedavisi ve sağlık göstergeleri. 39. Ulusal Hematoloji Kongresi 2013, P-113, Antalya.
  • Helvacı MR, Aydın Y, Ayyıldız O. Orak hücreli anemi ve talasemilerle birlikte olan orak hücre hastalıklarının şiddeti. 39. Ulusal Hematoloji Kongresi 2013, P-123, Antalya.
  • Helvacı MR, Selçuk A, Batmacı CY. Orak hücre hastalıklarının cinsiyete göre klinik şiddeti. 39. Ulusal Hematoloji Kongresi 2013, P-130, Antalya.
  • Helvacı MR, Erden EŞ, Aydın LY. Kronik tıkayıcı akciğer hastalığının orak hücre hastalığındaki aterosklerotik zemini. 39. Ulusal Hematoloji Kongresi 2013, P-133, Antalya.
  • Helvacı MR, Selçuk A, Varan G. Kırmızı küre desteği ve orak hücre hastalığında sağkalım. 39. Ulusal Hematoloji Kongresi 2013, P-134, Antalya.
  • Helvacı MR, Taner M, Cezgin K. Sirozun orak hücre hastalığındaki aterosklerotik zemini. 39. Ulusal Hematoloji Kongresi 2013, P-135, Antalya.
  • Helvacı MR, Taner M, Çiğdem HÇ. Kronik böbrek hastalığının orak hücre hastalığındaki aterosklerotik zemini. 39. Ulusal Hematoloji Kongresi 2013, P-137, Antalya.
  • Helvacı MR, Özdoğan M, Şerifler S, Acıpayam C, Davran R. Orak hücre hastalık şiddetinde otosplenektomi. 40. Ulusal Hematoloji Kongresi 2014, P-194, Antalya.
  • Helvacı MR, Yiğitbay M, Kurt A, Aydın Y, Gündoğdu M. Kanserde sigaraya bağlı damar sertliği. 40. Ulusal Hematoloji Kongresi 2014, P-396, Antalya.
  • Helvacı MR, Korkmaz A, Sevinç A, Camcı C, Keskin A. Sigara ve orak hücre hastalıkları. 40. Ulusal Hematoloji Kongresi 2014, P-192, Antalya.
  • Helvaci MR, Acipayam C, Buyukkaya E. Tonsilectomy in sickle cell diseases. 40. Ulusal Hematoloji Kongresi 2014, P-191, Antalya.
  • Helvacı MR, Hakimoğlu S, Bahadıroğlu V, Esen A, Koç S. Orak hücre hastalarında ameliyat öncesi hidroksiüre. 40. Ulusal Hematoloji Kongresi 2014, P-187, Antalya.
  • Helvacı MR, Aydoğan A, Akküçük S, Oruç C, Uğur M. Orak hücre hastalıkları ve ileus. 40. Ulusal Hematoloji Kongresi 2014, P-186, Antalya.
  • Helvacı MR, Aydoğan F, Sevinç A, Camcı C, Dilek İ. Platelet and white blood cell counts in severity of sickle cell diseases. 40. Ulusal Hematoloji Kongresi 2014, P-184, Antalya.
  • Helvacı MR, Sarıosmanoğlu MO, Kardaş S, Korkmaz Ö. Ağrılı krizler ve orak hücre hastalarında sağkalım. 40. Ulusal Hematoloji Kongresi 2014, P-170, Antalya.
  • Acıpayam C, Kaya S, Helvaci MR, İlhan G, Oktay G. C-reaktif proteinin çok yüksek seviyeleri orak hücreli hastalarda akut göğüs sendromu gelişimi için klinisyenleri uyarıcı olmalıdır. 40. Ulusal Hematoloji Kongresi 2014, P-178, Antalya.
  • Altıntaş E, Helvacı MR, Akbay E, Sezgin O. NAIV kronik hepatit C enfeksiyonu ile otoimmün tiroidit arasinda anlamlı bir ilişki var mıdır? Bir vaka kontrol çalışması. 21. Ulusal Gastroenteroloji Haftası 2004; sayfa 153.
  • Helvacı MR, Kaya H, Öksüz H, Topaloğlu C. Kronik miyeloid lösemide diffüz göz tutulumu. 34. Ulusal Hematoloji Kongresi 2008, B0083, İzmir.
  • Helvacı MR, Kaya H, Görgel A, Davran R, Canda MŞ. Kronik lenfositik lösemide yaygın akciğer tutulumu. 35. Ulusal Hematoloji Kongresi 2009, B4, Antalya.
  • Helvacı MR, Kaya H, Duman İ, Oktar S, Etcibaşı Ş. Orak hücreli anemide artmış demir yükü. 35. Ulusal Hematoloji Kongresi 2009, B10, Antalya.
  • Helvacı MR, Kaya H. Orak hücre hastalarında boy üzerine kalıtımın etkisi. 36. Ulusal Hematoloji Kongresi 2010, B019, Antalya.
  • Helvacı MR, Albayrak M, Balçık ÖŞ, Çelebi H, Ertekin F. Hematokrit değeri ve vücut kitle endeksi. 36. Ulusal Hematoloji Kongresi 2010, B022, Antalya.
  • Helvacı MR, Kaya H, Ertekin F. Kronik lenfositik lösemide tek kür fludarabin. 36. Ulusal Hematoloji Kongresi 2010, B028, Antalya.
  • Helvacı MR, Kaya H, Arı M. Orak hücre hastalığında narkotik bağımlılığının bayanlardaki sıklığı. 37. Ulusal Hematoloji Kongresi 2011, B016, Ankara.
    No content available to display!!!